XFOR

Healthcare Biotechnology

X4 Pharmaceuticals, Inc.

$2.90

+0.10 +3.57% today

Price History

Not enough data

Key Stats

Market Cap

287.53M

Avg Volume

837,563

P/E (TTM)

145.00

EPS

$0.02

52W High

$4.83

52W Low

$2.73

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-3.78

P/B Ratio

1.79

P/S Ratio

18.14

EV/EBITDA

-1.98

EV/Revenue

9.89

Margins

Gross Margin 81.5%

Operating Margin (186.1%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

346.3%

Return on Equity

(113.1%)

Return on Assets

(28.1%)

Liquidity & Leverage

Current Ratio

11.30

Quick Ratio

10.85

Debt / Equity

0.50

Total Cash

207.97M

Total Debt

77.22M

About

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.